Literature DB >> 14695659

Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course.

Koen Van Herck1, Pierre Van Damme, Marc Lievens, Michel Stoffel.   

Abstract

Vaccine-induced hepatitis A antibodies persist up to 10 years in adults, with mathematical models estimating further persistence up to 20-25 years. Thirty-one adults received booster inoculations 12 years after their initial vaccination (Havrix 720 El.U at months 0, 1, 6). At the time of booster inoculation, all still had detectable antibodies. All but one subject met pre-defined criteria for anamnestic response 14 days after the booster, and all subjects did so after 30 days. The subjects' geometric mean titre (GMT) increased rapidly from 242 IU/L at baseline to 3,832 IU/L at day 14 and 5,282 IU/L at day 30. This study shows a substantial immune response to re-exposure to hepatitis A antigen after 12 years, which occurs rapidly to ensure protection within the average incubation period of hepatitis A virus. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14695659     DOI: 10.1002/jmv.10574

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  9 in total

1.  Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults.

Authors:  Nancy F Crum-Cianflone; Kenneth Wilkins; Andrew W Lee; Anthony Grosso; Michael L Landrum; Amy Weintrob; Anuradha Ganesan; Jason Maguire; Stephanie Klopfer; Carolyn Brandt; William P Bradley; Mark R Wallace; Brian K Agan
Journal:  J Infect Dis       Date:  2011-06-15       Impact factor: 5.226

2.  Hepatitis a and e infection in international travellers.

Authors:  Joseph Torresi; Douglas Johnson
Journal:  Curr Infect Dis Rep       Date:  2011-06       Impact factor: 3.725

Review 3.  Immunization against Hepatitis A.

Authors:  Daniel Shouval
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

4.  Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques.

Authors:  Jian Yan; Kristina Harris; Amir S Khan; Ruxandra Draghia-Akli; Duane Sewell; David B Weiner
Journal:  Vaccine       Date:  2008-04-14       Impact factor: 3.641

5.  Fatal outcome of hepatitis A virus (HAV) infection in a traveler with incomplete HAV vaccination and evidence of Rift Valley Fever virus infection.

Authors:  Anke Oltmann; Stephanie Kämper; Oliver Staeck; Jonas Schmidt-Chanasit; Stephan Günther; Thomas Berg; Christina Frank; Detlev H Krüger; Jörg Hofmann
Journal:  J Clin Microbiol       Date:  2008-09-03       Impact factor: 5.948

6.  Persistence of seropositivity among persons vaccinated for hepatitis A during infancy by maternal antibody status: 15-year follow-up.

Authors:  Philip R Spradling; Lisa R Bulkow; Susan E Negus; Chriss Homan; Michael G Bruce; Brian J McMahon
Journal:  Hepatology       Date:  2016-02-01       Impact factor: 17.425

7.  Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen.

Authors:  Jian Yan; Dawn K Reichenbach; Natasha Corbitt; David A Hokey; Mathura P Ramanathan; Kibwei A McKinney; David B Weiner; Duane Sewell
Journal:  Vaccine       Date:  2008-11-18       Impact factor: 3.641

Review 8.  Hepatitis A vaccination and its immunological and epidemiological long-term effects - a review of the evidence.

Authors:  Christian Herzog; Koen Van Herck; Pierre Van Damme
Journal:  Hum Vaccin Immunother       Date:  2020-12-16       Impact factor: 3.452

9.  Persistence of immunity from 1 year of age after one or two doses of hepatitis A vaccine given to children in Argentina.

Authors:  Carlos Espul; Laura Benedetti; Héctor Cuello; Guy Houillon; Anvar Rasuli
Journal:  Hepat Med       Date:  2012-08-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.